HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102
BIOA•Phase 2 trial begins for BGE-102
- HitGen partner BioAge Labs dosed the first participant in a Phase 2 trial of BGE-102, a novel oral NLRP3 inhibitor for cardiovascular risk reduction.
Reuters source text: ID:nPn33Mhvsa
